Jabil 10-K: FY2026 Revenue Up 20.6% to $36.0B; FDA Warning Letter Disclosed
JBL sits 46% above its 52-week low of $189.6.
Summary
Jabil's FY2026 10-K confirms 20.6% revenue growth to $36.0B and $9.75 diluted EPS, and newly discloses an FDA Warning Letter at its Pii facility plus FY2027 capex guidance of 1.5%-2.0% of revenue.
Key Events · Earnings and Guidance · JBL
-
FY2026 Revenue Jumps 20.6% to $36.0B
Net revenue rose to $35,954M from $29,802M, with net income attributable to Jabil of $1,042M and diluted EPS of $9.75 (core EPS $13.09).
-
Intelligent Infrastructure Drives Growth
Segment revenue grew 45% to $17,872M, led by a 33% increase in cloud and data center infrastructure on AI demand; segment income rose to $1,069M from $664M.
-
FDA Warning Letter at Pii Facility
Jabil received an FDA Warning Letter on August 27, 2026 tied to a March 2026 inspection of the Pharmaceutics International facility in Hunt Valley, Maryland; manufacturing is paused pending an approved remediation plan.
-
FY2027 Capex Guidance Set
Management expects net capital expenditures of 1.5% to 2.0% of net revenue in fiscal 2027.
Analysis · JBL · Manufacturing
The audited FY2026 numbers confirm the strong quarter Jabil reported on September 30: revenue of $35.95B (up 20.6%), net income of $1.04B and diluted EPS of $9.75, with core EPS of $13.09. Intelligent Infrastructure is the growth engine, up 45% on AI data-center demand. What investors have not seen before is an FDA Warning Letter, received August 27, 2026, tied to the Pii facility in Hunt Valley, Maryland, where manufacturing has been paused pending remediation; FY2027 capex guidance of 1.5%-2.0% of revenue is also new. The company further detailed a $1.5B 2027 buyback with $898M remaining as of October 20, 2026. The FDA issue is a contained, single-site regulatory overhang rather than a company-wide problem, but it is the first time investors are hearing about it.
How filings like this one have moved
In the 30 days to Oct 23, 2026, 29.2% of the 1549 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JBL was trading at $276.22 on NYSE in the Manufacturing sector, with a market capitalization of approximately $28.7B. The 52-week trading range was $189.60 to $428.93. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.